DOCSLIB.ORG

Extensive Swelling After Booster Doses of Acellular Pertussis–Tetanus–Diphtheria Vaccines

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Extensive Swelling After Booster Doses of Acellular Pertussis–Tetanus–Diphtheria Vaccines Extensive Swelling After Booster Doses of Acellular Pertussis–Tetanus–Diphtheria Vaccines Margaret B. Rennels, MD*; Maria A. Deloria, BS‡; Michael E. Pichichero, MD§; Genevieve A. Losonsky, MD*; Janet A. Englund, MDi; Bruce D. Meade, PhD¶; Edwin L. Anderson, MD**; Mark C. Steinhoff, MD#; and Kathryn M. Edwards, MD‡‡ ABSTRACT. Background. Diphtheria and tetanus tox- antibody to diphtheria, tetanus, or pertussis toxin and oid combined with acellular pertussis (DTaP) vaccines rates of swelling of the whole thigh. are less reactogenic than diphtheria and tetanus toxoid Conclusions. Booster doses of DTaP vaccines can combined with whole cell pertussis (DTwP) vaccines. cause entire limb swelling, which is usually associated However, local reactions increase in rate and severity with redness and pain. Our data suggest that this exten- with each successive DTaP dose, and swelling of the entire sive swelling reaction may be more common with vac- injected limb has been reported after booster doses. cines containing high diphtheria toxoid content. Methods. We reviewed reports of swelling of the en- Pediatrics 2000;105(1). URL: http://www.pediatrics.org/ tire thigh or upper arm after the fourth and fifth dose, cgi/content/full/105/1/e12; pertussis, reactions, vaccine, respectively, of DTaP vaccines administered in the Na- diphtheria, toxoid. tional Institutes of Health multicenter comparative DTaP studies. Relationships were explored among reports of se- vere swelling, rates of other reactions, quantity of vaccine ABBREVIATIONS. DTaP, acellular pertussis combined with teta- contents, and prevaccination and postvaccination antibody nus and diphtheria toxoid vaccines; DTwP, whole cell pertussis levels to pertussis toxin, tetanus toxin, and diphtheria toxin. combined with tetanus and diphtheria toxoid vaccines; Ptxn, per- Results. Entire thigh swelling was an unsolicited re- tussis toxin; Dtxn, diphtheria toxin; Ttxn, tetanus toxin; Dtxd, diphtheria toxoid; Ttxd, tetanus toxoid; CBER, Center for Biologi- action reported in 20 (2%) of the 1015 children who re- cals Evaluation and Research. ceived 4 consecutive doses of the same DTaP vaccine. The reaction was associated with 9 of the 12 DTaP vac- cines evaluated. Although there were no reports of swell- cellular pertussis combined with tetanus and ing of the entire upper arm in 121 children given a fifth diphtheria toxoid vaccines (DTaP) have con- dose of the same DTaP, 4 (2.7%) of 146 recipients of 5 sistently been shown to be less reactogenic doses of a mixed schedule of DTaP vaccines experienced A than whole cell pertussis combined with tetanus and such swelling. Rates of other reactions were higher in 1–4 children with entire thigh swelling than in those with- diphtheria toxoid vaccines (DTwP). Some practi- out. Of the children with entire thigh swelling, 60% had tioners and parents therefore may have the impres- local pain, and 60% had erythema. All swelling subsided sion that DTaP injection is free of side effects. It is spontaneously without sequelae. There was a significant now well-established that rates of local reactions in- linear association between the rates of entire thigh swell- crease with each subsequent dose of DTaP vaccine.3–7 ing after dose 4 and diphtheria toxoid content in the Indeed, there have been 2 published reports of swell- DTaP products. Lesser degrees of swelling (>50 mm but ing of the entire injected thigh after a fourth consec- less than entire limb) correlated with pertussis toxoid utive dose of 2- and 3-component DTaP vaccines.8,9 content after dose 4 and aluminum content after dose 5. We studied the rate at which swelling of the entire No relationship was established between levels of serum injected muscle was spontaneously reported after booster doses of DTaP vaccines and ascertained whether it occurred with different DTaP products. From the *University of Maryland School of Medicine, Baltimore, Mary- Reaction forms filled out by parents of children par- land; ‡National Institute of Allergy and Infectious Diseases, National Insti- tute of Health, Bethesda, Maryland; §University of Rochester School of ticipating in the National Institutes of Health-sup- Medicine, Rochester, New York; iBaylor College of Medicine, Houston, ported multicenter trials of the safety and immuno- Texas; ¶Center for Biologicals Evaluation and Research, Food and Drug genicity of fourth and fifth consecutive doses of Administration, Bethesda, Maryland; #Johns Hopkins School of Public various DTaP vaccines were reviewed. Associated Health, Baltimore, Maryland; **St Louis University School of Medicine, St Louis, Missouri; ‡‡Vanderbilt University School of Medicine, Nashville, reactions were evaluated to examine whether swell- Tennessee. ing of the entire muscle was a benign reactive edema, This work was presented in part at the Academic Pediatric Societies’ An- as had been reported previously,9 or whether associ- nual Meeting; May 3, 1998; New Orleans, LA. ated symptoms were present. Additionally, to ex- The content of this presentation does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does the plore whether there was a relationship between se- mention of trade names, commercial products, or organizations imply vere swelling and the quantity of a particular endorsement by the US Government. component in the involved vaccines, rates of entire Received for publication May 19, 1999; accepted Aug 12, 1999. limb swelling and swelling .50 mm (excluding Reprint requests to (M.B.R.) 22 S Greene St, Baltimore, MD 21201. E-mail: [email protected] those with whole limb swelling) were correlated PEDIATRICS (ISSN 0031 4005). Copyright © 2000 by the American Acad- with the content of selected different antigens con- emy of Pediatrics. tained in the vaccines. Finally, the pre- and post- http://www.pediatrics.org/cgi/content/full/105/1/Downloaded from www.aappublications.org/newse12 PEDIATRICS by guest on October Vol. 1, 1052021 No. 1 January 2000 1of6 fourth dose levels of antibodies to pertussis toxin $100.1°F. Temperatures were measured rectally after dose 4 and (Ptxn), diphtheria toxin (Dtxn), and tetanus toxin by mouth after dose 5. Reaction forms had separate spaces at the bottom for the parent to write in comments, other reactions, or any (Ttxn) were compared between children with, and physician visit. Study nurses, who were unaware of what vaccine without, entire limb swelling to explore whether an- the child had received, phoned the family on days 1 and 3 after tigen–antibody interaction might explain the exten- vaccination to obtain reaction data. Diary cards were collected sive swelling reaction. from the parents at the time of the postvaccination blood draw. Children were determined to have experienced entire thigh or METHODS deltoid swelling only if the parent wrote in the comments section that the entire thigh or upper arm was swollen, respectively. A Subjects subset of these children were seen by study personnel who con- The methods of these trials were published previously.3,4 firmed parental descriptions. Healthy 15- to 20-month-old children who had received a primary series of 1 of 13 DTaP vaccines or 1 of 2 DTwP vaccines at 2, 4, and Serology 6 months of age in a National Institutes of Health-supported Antibody measurements were performed on blood samples multicenter trial were invited to enroll into a fourth dose booster obtained immediately before and ;1 month after the fourth dose study in which children were given the same DTaP or DTwP, as of vaccine. For antibody to the pertussis antigens, results obtained administered in the primary series. A fifth dose of the Lederle previously3 were used in analyses. Serum diphtheria and tetanus DTwP vaccine or 1 of 6 of these DTaP vaccines was administered antitoxin levels were determined at the University of Maryland in to a subset of these children at 4 to 6 years of age. Children children who experienced entire thigh swelling after the fourth received a different vaccine at dose 4 or 5 if the vaccine given for dose of DTaP, and in 2 randomly selected control children per case the previous doses was not available. This study primarily ana- who received the same vaccine but had no thigh swelling. Neu- lyzed the children who received the same vaccine for all 4 or 5 tralizing antibody to Dtxn was measured in the Vero-cell assay doses. The trial was conducted through the 6 National Institutes of developed by Gupta et al10 and adapted by M. C. Anderson, Health supported Vaccine Evaluation Units: Baylor College of Center for Biologicals Evaluation and Research (CBER), Food and Medicine, Houston, TX; Johns Hopkins University School of Pub- Drug Administration. The assay was calibrated through use of lic Health, Baltimore, MD; St Louis University School of Medicine, reference antitoxin lot 451 with a unitage of 4 U/mL obtained St Louis, MO; University of Maryland School of Medicine, Balti- from CBER. This antitoxin was a freeze-dried preparation of the more, MD; University of Rochester School of Medicine, Rochester, US standard diphtheria antitoxin. Diphtheria toxin (lot 35 119 NY; and Vanderbilt University, Nashville, TN. The study was from CBER) was used at a concentration of .8 Lf/mL, allowing an approved by the institutional review boards of each participating assay sensitivity of .01 anti-toxin U/mL. Tetanus antitoxin levels center and written informed consent was obtained from a parent were measured by enzyme-linked immunosorbent assay by pre- or guardian before enrollment. viously
Load more

Recommended publications
  • Systematic Booster After Rabies Pre-Exposure Prophylaxis to Alleviate Rabies Antibody Monitoring in Individuals at Risk of Occupational Exposure
    Article Systematic Booster after Rabies Pre-Exposure Prophylaxis to Alleviate Rabies Antibody Monitoring in Individuals at Risk of Occupational Exposure Perrine Parize 1,*, Jérémie Sommé 2 , Laura Schaeffer 3, Florence Ribadeau-Dumas 1, Sheherazade Benabdelkader 1, Agnès Durand 4, Arnaud Tarantola 1, Johann Cailhol 5, Julia Goesch 5, Lauriane Kergoat 1 , Anne-Sophie Le Guern 6, Marie-Laurence Mousel 2, Laurent Dacheux 1 , Paul-Henri Consigny 5, Arnaud Fontanet 3,7, Beata Francuz 2 and Hervé Bourhy 1 1 Institut Pasteur, Unit Lyssavirus Epidemiology and Neuropathology, National Reference Center for Rabies and WHO Collaborating Centre for Reference and Research on Rabies, 75015 Paris, France; fl[email protected] (F.R.-D.); [email protected] (S.B.); [email protected] (A.T.); [email protected] (L.K.); [email protected] (L.D.); [email protected] (H.B.) 2 Institut Pasteur, Occupational Health Department, 75015 Paris, France; [email protected] (J.S.); [email protected] (M.-L.M.); [email protected] (B.F.) 3 Institut Pasteur, Emerging Diseases Epidemiology Unit, Centre for Global Health Research and Education, 75015 Paris, France; [email protected] (L.S.); [email protected] (A.F.) 4 Laboratoire Cerballiance, 75017 Paris, France; [email protected] 5 Citation: Parize, P.; Sommé, J.; Institut Pasteur, Centre Médical, Centre d’Infectiologie Necker-Pasteur, 75015 Paris, France; Schaeffer, L.; Ribadeau-Dumas, F.; [email protected] (J.C.); [email protected] (J.G.); [email protected] (P.-H.C.) 6 Benabdelkader, S.; Durand, A.; Institut Pasteur, Laboratory of the Medical Center, 75015 Paris, France; [email protected] 7 Conservatoire National des Arts et Métiers, 75003 Paris, France Tarantola, A.; Cailhol, J.; Goesch, J.; * Correspondence: [email protected]; Tel.: +33-140-613-436 Kergoat, L.; et al.
    [Show full text]
  • COVID-19 Vaccination Programme: Information for Healthcare Practitioners
    COVID-19 vaccination programme Information for healthcare practitioners Republished 6 August 2021 Version 3.10 1 COVID-19 vaccination programme: Information for healthcare practitioners Document information This document was originally published provisionally, ahead of authorisation of any COVID-19 vaccine in the UK, to provide information to those involved in the COVID-19 national vaccination programme before it began in December 2020. Following authorisation for temporary supply by the UK Department of Health and Social Care and the Medicines and Healthcare products Regulatory Agency being given to the COVID-19 Vaccine Pfizer BioNTech on 2 December 2020, the COVID-19 Vaccine AstraZeneca on 30 December 2020 and the COVID-19 Vaccine Moderna on 8 January 2021, this document has been updated to provide specific information about the storage and preparation of these vaccines. Information about any other COVID-19 vaccines which are given regulatory approval will be added when this occurs. The information in this document was correct at time of publication. As COVID-19 is an evolving disease, much is still being learned about both the disease and the vaccines which have been developed to prevent it. For this reason, some information may change. Updates will be made to this document as new information becomes available. Please use the online version to ensure you are accessing the latest version. 2 COVID-19 vaccination programme: Information for healthcare practitioners Document revision information Version Details Date number 1.0 Document created 27 November 2020 2.0 Vaccine specific information about the COVID-19 mRNA 4 Vaccine BNT162b2 (Pfizer BioNTech) added December 2020 2.1 1.
    [Show full text]
  • Statements Contained in This Release As the Result of New Information Or Future Events Or Developments
    Pfizer and BioNTech Provide Update on Booster Program in Light of the Delta-Variant NEW YORK and MAINZ, GERMANY, July 8, 2021 — As part of Pfizer’s and BioNTech’s continued efforts to stay ahead of the virus causing COVID-19 and circulating mutations, the companies are providing an update on their comprehensive booster strategy. Pfizer and BioNTech have seen encouraging data in the ongoing booster trial of a third dose of the current BNT162b2 vaccine. Initial data from the study demonstrate that a booster dose given 6 months after the second dose has a consistent tolerability profile while eliciting high neutralization titers against the wild type and the Beta variant, which are 5 to 10 times higher than after two primary doses. The companies expect to publish more definitive data soon as well as in a peer-reviewed journal and plan to submit the data to the FDA, EMA and other regulatory authorities in the coming weeks. In addition, data from a recent Nature paper demonstrate that immune sera obtained shortly after dose 2 of the primary two dose series of BNT162b2 have strong neutralization titers against the Delta variant (B.1.617.2 lineage) in laboratory tests. The companies anticipate that a third dose will boost those antibody titers even higher, similar to how the third dose performs for the Beta variant (B.1.351). Pfizer and BioNTech are conducting preclinical and clinical tests to confirm this hypothesis. While Pfizer and BioNTech believe a third dose of BNT162b2 has the potential to preserve the highest levels of protective efficacy against all currently known variants including Delta, the companies are remaining vigilant and are developing an updated version of the Pfizer-BioNTech COVID-19 vaccine that targets the full spike protein of the Delta variant.
    [Show full text]
  • COVID-19 Vaccines Frequently Asked Questions
    Page 1 of 12 COVID-19 Vaccines 2020a Frequently Asked Questions Michigan.gov/Coronavirus The information in this document will change frequently as we learn more about COVID-19 vaccines. There is a lot we are learning as the pandemic and COVID-19 vaccines evolve. The approach in Michigan will adapt as we learn more. September 29, 2021. Quick Links What’s new | Why COVID-19 vaccination is important | Booster and additional doses | What to expect when you get vaccinated | Safety of the vaccine | Vaccine distribution/prioritization | Additional vaccine information | Protecting your privacy | Where can I get more information? What’s new − Pfizer booster doses recommended for some people to boost waning immunity six months after completing the Pfizer vaccine. Why COVID-19 vaccination is important − If you are fully vaccinated, you don’t have to quarantine after being exposed to COVID-19, as long as you don’t have symptoms. This means missing less work, school, sports and other activities. − COVID-19 vaccination is the safest way to build protection. COVID-19 is still a threat, especially to people who are unvaccinated. Some people who get COVID-19 can become severely ill, which could result in hospitalization, and some people have ongoing health problems several weeks or even longer after getting infected. Even people who did not have symptoms when they were infected can have these ongoing health problems. − After you are fully vaccinated for COVID-19, you can resume many activities that you did before the pandemic. CDC recommends that fully vaccinated people wear a mask in public indoor settings if they are in an area of substantial or high transmission.
    [Show full text]
  • GRADE Table 4. Is There a Need for a Booster Dose Following Immunization Wi
    GRADE Table 4. Is there a need for a booster dose following immunization with the primary series of inactivated Vero cell-derived JE vaccine in individuals living in JE-endemic areas? Population : Immunocompetent individuals living in JE-endemic areas Intervention: Two doses (primary series) of inactivated Vero cell-derived vaccine administered ≥12 months previously Comparison: Placebo/no vaccination/other JE vaccine Outcome : JE disease (immunogenicity accepted) Is there need for a booster dose following immunization with the primary series of inactivated Vero cell-derived JE vaccine in individuals living in JE-endemic areas? Rating Adjustment to rating No. of studies/starting rating 4 RCTs1 4 Limitation in 2 Serious -1 study design Inconsistency None serious 0 Factors decreasing Indirectness Serious3,4 -1 confidence Imprecision None serious 0 Publication bias None serious 0 Large effect Not applicable5 0 Quality Assessment Quality Factors increasing Dose-response Not applicable 0 confidence Antagonistic bias Not applicable 0 and confounding Final numerical rating of quality of evidence 2 Evidence supports limited confidence in the estimate Statement on quality of evidence of the effect on the health outcome. A primary series of inactivated Vero cell- derived JE vaccines administered to children in endemic settings elicits seroprotective neutralizing Conclusion antibody titres for at least 3 years after the primary immunization. Summary of Findings of Summary Based on a review of data on IXIARO 1Five clinical studies following participants 12 months post-primary series, 2 years, or 3 years are available, limiting the full assessment of long-term protection. Data in adults from non-endemic settings suggest a decline in seroprotection rates and GMTs in the 24 months following primary immunization.
    [Show full text]
  • Hepatitis B and Healthcare Personnelq &A IAC Answers Frequently Asked Questions About How to Protect Healthcare Personnel
    Hepatitis B and Healthcare PersonnelQ &A IAC answers frequently asked questions about how to protect healthcare personnel Experts from the Immunization Action Engerix-B (GSK) or Recombivax HB (Merck) should be vaccinated against hepatitis B if Coalition (IAC) answer your questions may be completed with Heplisav-B. However, they haven’t been previously vaccinated. about hepatitis B (HepB) vaccine. You’ll data are limited on the safety and immunoge- Receipt of the vaccine is not a reason to dis- nicity effects when Heplisav-B is interchanged continue breast-feeding. find additional &Q As about hepatitis B with hepatitis B vaccines from other manufac- There are no clinical studies of Heplisav-B in vaccine on the “Ask the Experts” section turers. When feasible, the same manufactur- pregnant women. Available human data on of immunize.org at www.immunize.org/ er’s vaccines should be used to complete the Heplisav-B administered to pregnant women askexperts/experts_hepb.asp series. However, vaccination should not be are insufficient to assess vaccine-associated deferred when the manufacturer of the previ- risks in pregnancy. Until safety data are avail- ously administered vaccine is unknown or able for Heplisav-B, providers should con- Hepatitis B Vaccination when the vaccine from the same manufac- tinue to vaccinate pregnant women needing turer is unavailable. hepatitis B vaccination with a vaccine from Which people who work in healthcare settings The 2-dose hepatitis B vaccine series only a different manufacturer. need hepatitis B vaccine? applies when both doses in the series consist Is there a recommendation for routine booster The Occupational Safety and Health Adminis- of Heplisav-B.
    [Show full text]
  • Developing a Vaccine Against HIV Infection
    Developing a vaccine against HIV infection KEY POINTS Researchers have been working on an HIV vaccine since the 1980s, but progress towards an effective vaccine has been much slower than anticipated. Finding at least a partially effective vaccine remains of critical importance for the HIV response. The biggest reduction in new infections would be achieved by a combination of PrEP, universal antiretroviral treatment for people already living with HIV, and a vaccine.1 An HIV vaccine is a more realistic prospect today than a decade ago and an optimistic forecast of HIV vaccine availability is that one might be available by 2030. Explore this page to find out more about the need for a vaccine against HIV, challenges in vaccine development, progress in developing a vaccine and achieving an effective vaccine for HIV. What is an HIV vaccine? Today, an effective vaccine against HIV does not exist. A vaccine that can prevent infection would teach the immune system to respond to HIV by making antibodies that can bind to the virus and stop it from infecting cells, or by promoting other immune responses that kill the virus. No vaccine is 100% effective, and this is likely to be the same for HIV. Some people who receive a vaccine will not respond strongly enough to the vaccine and will not be protected, as in the case of the seasonal flu vaccine. But finding at least a partially effective vaccine remains of critical importance for the HIV response, as all successful disease elimination strategies have included a vaccine among their arsenal. The need for a vaccine against HIV UNAIDS estimates that 1.8 million people became infected with HIV in 2017, 36.9 million people were living with HIV and 21.7 million were receiving antiretroviral therapy.
    [Show full text]
  • Vaccinations for Pregnant Women the Table Below Shows Which Vaccinations You May Or May Not Need During Your Pregnancy
    Vaccinations for Pregnant Women The table below shows which vaccinations you may or may not need during your pregnancy. Vaccine Do you need it during your pregnancy? Influenza Yes! You need a flu shot every fall (or even as late as winter or spring) for your protection and for the protection of your baby and others around you. It’s safe to get the vaccine at any time during your pregnancy. Tetanus, diphtheria, Yes! Women who are pregnant need a dose of Tdap vaccine (the adult whooping cough vaccine) during each pregnancy, prefer- whooping cough ably in the early part of the third trimester. It’s safe to be given during pregnancy and will help protect your baby from whooping (pertussis) cough in the first few months after birth when he or she is most vulnerable. After Tdap, you need a Tdap or Td booster dose every Tdap, Td 10 years. Consult your healthcare provider if you haven’t had at least 3 tetanus- and diphtheria-toxoid containing shots some- time in your life or if you have a deep or dirty wound. Human No. This vaccine is not recommended to be given during pregnancy, but if you inadvertently receive it, this is not a cause for papillomavirus concern. HPV vaccine is recommended for all people age 26 or younger, so if you are in this age group, make sure you are HPV vaccinated before or after your pregnancy. People age 27 through 45 may also be vaccinated against HPV after discussion with their healthcare provider. The vaccine is given in 2 or 3 doses (depending on the age at which the first dose is given) over a 6-month period.
    [Show full text]
  • Vaccine Immunology Claire-Anne Siegrist
    2 Vaccine Immunology Claire-Anne Siegrist To generate vaccine-mediated protection is a complex chal- non–antigen-specifc responses possibly leading to allergy, lenge. Currently available vaccines have largely been devel- autoimmunity, or even premature death—are being raised. oped empirically, with little or no understanding of how they Certain “off-targets effects” of vaccines have also been recog- activate the immune system. Their early protective effcacy is nized and call for studies to quantify their impact and identify primarily conferred by the induction of antigen-specifc anti- the mechanisms at play. The objective of this chapter is to bodies (Box 2.1). However, there is more to antibody- extract from the complex and rapidly evolving feld of immu- mediated protection than the peak of vaccine-induced nology the main concepts that are useful to better address antibody titers. The quality of such antibodies (e.g., their these important questions. avidity, specifcity, or neutralizing capacity) has been identi- fed as a determining factor in effcacy. Long-term protection HOW DO VACCINES MEDIATE PROTECTION? requires the persistence of vaccine antibodies above protective thresholds and/or the maintenance of immune memory cells Vaccines protect by inducing effector mechanisms (cells or capable of rapid and effective reactivation with subsequent molecules) capable of rapidly controlling replicating patho- microbial exposure. The determinants of immune memory gens or inactivating their toxic components. Vaccine-induced induction, as well as the relative contribution of persisting immune effectors (Table 2.1) are essentially antibodies— antibodies and of immune memory to protection against spe- produced by B lymphocytes—capable of binding specifcally cifc diseases, are essential parameters of long-term vaccine to a toxin or a pathogen.2 Other potential effectors are cyto- effcacy.
    [Show full text]
  • Pneumococcal Conjugate Vaccine Breakthrough Infections: 2001–2016 Tolulope A
    Pneumococcal Conjugate Vaccine Breakthrough Infections: 2001–2016 Tolulope A. Adebanjo, MD, MPH,a,b Tracy Pondo, MSPH,a David Yankey, PhD, MPH,b Holly A. Hill, MD, PhD,b Ryan Gierke, MPH,a Mirasol Apostol, MPH,c Meghan Barnes, MSPH,d Susan Petit, MPH,e Monica Farley, MD,f Lee H. Harrison, MD,g Corinne Holtzman, MPH,h Joan Baumbach, MD,i Nancy Bennett, MD, MS,j Suzanne McGuire, MPH,k Ann Thomas, MD, MPH,l William Schaffner, MD,m Bernard Beall, PhD,b Cynthia G. Whitney, MD, MPH,b Tamara Pilishvili, PhD, MPHb BACKGROUND: Most countries use 3-dose pneumococcal conjugate vaccine (PCV) schedules; abstract a4-dose(3primaryand1booster)scheduleislicensed for US infants. We evaluated the invasive pneumococcal disease (IPD) breakthrough infection incidence in children receiving 2 vs 3 primary PCV doses with and without booster doses (2 1 1vs31 1; 2 1 0vs31 0). METHODS: We used 2001–2016 Active Bacterial Core surveillance data to identify breakthrough infections (vaccine-type IPD in children receiving $1 7-valent pneumococcal conjugate vaccine [PCV7] or 13-valent pneumococcal conjugate vaccine [PCV13] dose) among children aged ,5 years. We estimated schedule-specific IPD incidence rates (IRs) per 100 000 person- years and compared incidence by schedule (2 1 1vs31 1; 2 1 0vs31 0) using rate differences (RDs) and incidence rate ratios. RESULTS: We identified 71 PCV7 and 49 PCV13 breakthrough infections among children receiving a schedule of interest. PCV13 breakthrough infection rates were higher in children aged ,1 year receiving the 2 1 0 (IR: 7.8) vs 3 1 0 (IR: 0.6) schedule (incidence rate ratio: 12.9; 95% confidence interval: 4.1–40.4); PCV7 results were similar.
    [Show full text]
  • Green Book Chapter Pneumococcal Disease
    Chapter 25: Pneumococcal January 2018 25 Pneumococcal Pneumococcal meningitis NOTIFIABLE Pneumococcal The disease Pneumococcal disease is the term used to describe infections caused by the bacterium Streptococcus pneumoniae (also called pneumococcus). S. pneumoniae is an encapsulated Gram-positive coccus. The capsule is the most important virulence factor of S. pneumoniae; pneumococci that lack the capsule are normally not virulent. Over 90 different capsular types have been characterised. Prior to the routine conjugate vaccination, around 69% of invasive pneumococcal infections were caused by the ten (14, 9V, 1, 8, 23F, 4, 3, 6B, 19F, 7F) most prevalent serotypes (Trotter et al., 2010). Some serotypes of the pneumococcus may be carried in the nasopharynx without symptoms, with disease occurring in a small proportion of infected individuals. Other serotypes are rarely identified in the nasopharynx but are associated with invasive disease. The incubation period for pneumococcal disease is not clearly defined but it may be as short as one to three days. The organism may spread locally into the sinuses or middle ear cavity, causing sinusitis or otitis media. It may also affect the lungs to cause pneumonia, or cause systemic (invasive) infections including bacteraemic pneumonia, bacteraemia and meningitis. Transmission is by aerosol, droplets or direct contact with respiratory secretions of someone carrying the organism. Transmission usually requires either frequent or prolonged close contact. There is a seasonal variation in pneumococcal disease, with peak levels in the winter months. Invasive pneumococcal disease is a major cause of morbidity and mortality. It particularly affects the very young, the elderly, those with an absent or non-functioning spleen and those with other causes of impaired immunity.
    [Show full text]
  • Differences in the Concentration of Anti-SARS-Cov-2 Igg Antibodies Post-COVID-19 Recovery Or Post-Vaccination
    cells Article Differences in the Concentration of Anti-SARS-CoV-2 IgG Antibodies Post-COVID-19 Recovery or Post-Vaccination Andrzej Tretyn 1,† , Joanna Szczepanek 2,*,† , Monika Skorupa 1,2 , Joanna Jarkiewicz-Tretyn 3, Dorota Sandomierz 3, Joanna Dejewska 1,3, Karolina Ciechanowska 3, Aleksander Jarkiewicz-Tretyn 3,4, Wojciech Koper 5 and Krzysztof Pałgan 6 1 Faculty of Biological and Veterinary Sciences, Nicolaus Copernicus University, 87-100 Torun, Poland; [email protected] (A.T.); [email protected] (M.S.); [email protected] (J.D.) 2 Centre for Modern Interdisciplinary Technologies, Nicolaus Copernicus University, ul. Wilenska 4, 87-100 Torun, Poland 3 Non-Public Health Care Centre, Cancer Genetics Laboratory, 87-100 Torun, Poland; [email protected] (J.J.-T.); [email protected] (D.S.); [email protected] (K.C.); [email protected] (A.J.-T.) 4 Polish-Japanese Academy of Information Technology, 02-008 Warszawa, Poland 5 The Voivodeship Sanitary-Epidemiological Station in Bydgoszcz, 85-031 Bydgoszcz, Poland; [email protected] 6 Department of Allergology, Clinical Immunology and Internal Diseases, Collegium Medicum, Nicolaus Copernicus University, 85-067 Bydgoszcz, Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-056-665-6080 † These authors contributed equally to this work. Citation: Tretyn, A.; Szczepanek, J.; Skorupa, M.; Jarkiewicz-Tretyn, J.; Abstract: At the end of 2020, population-based vaccination programs with new generation mRNA- Sandomierz, D.; Dejewska, J.; based vaccines began almost all over the world. The aim of the study was to evaluate the titer of Ciechanowska, K.; Jarkiewicz-Tretyn, anti-SARS-CoV-2 IgG antibodies against the S1 subunit of the virus’s spike protein as a marker of the A.; Koper, W.; Pałgan, K.
    [Show full text]